CME; prostate cancer, CRPC, kidney cancer, renal cell

Overview
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Ignacio Duran, MD
Medical Oncology Department
Hospital Universitario Virgen del Rocio
Seville, Spain
Dr. Duran has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: AstraZeneca, Roche, Gilead
Consulting fees: BMS, MSD, Bayer, Johnson and Johnson, Merck, Astellas
Other (Travel expenses related to conference attendance): Bayer, Ipsen, AstraZeneca
Sandy Srinivas, MD
Professor of Medicine
Stanford University
Stanford, CA
Dr. Srinivas has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: REGN, Merkc, Bayer, SEAGN
Consulting fees: Novartis, Telix, Lilly, Janssen, Aveoad
Wenxin Xu, MD
Assistant Professor of Medicine
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute / Harvard Medical School
Boston, MA
Dr. Xu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: Oncohost, Arsenal Biosciences, Merck
Consulting fees: Eisai, Exelixis, Xencor, Jazz, Aveo, Merck, Celdara, Deciphera
Reviewers/Content Planners/Authors:
- Tim Person has nothing to disclose.
- Jocelyn Timko has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Deborah Freedman-Cass, PhD, has nothing to disclose.
- Bailee Sliker, PhD, has nothing to disclose.
- MaryElizabeth Stein, PhD, has nothing to disclose
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Implement guideline-adherent care for patients with genitourinary malignancies
- Formulate treatment strategies based on evidence and guidelines for genitourinary malignancies across the disease spectrum
- Interpret emerging data with the potential to influence practice guidelines for patients with genitourinary malignancies
- Employ region-specific treatment tactics aligned with NCCN Guidelines for patients with genitourinary malignancies
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with Genitourinary Cancers (GU).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity. 
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hour/0.125 CEUs of pharmacy contact hours.
 
The Universal Activity Number for this program is JA0006235-0000-24-134-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).  
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credit(s). Approval is valid until 12/20/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)

Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Eisai, Exelixis, Inc., and Pfizer, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Prova Education, and the educational collaborators. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/20/2024
Expiration Date: 12/20/2025